Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Boston, MA
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Boston, MA
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Worcester, MA
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Worcester, MA
Click here to add this to my saved trials
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Rochester, MN
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Hackensack, NJ
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
New Brunswick, NJ
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
New York, NY
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Chapel Hill, NC
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Charlotte, NC
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Wyomissing, PA
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Wyomissing, PA
Click here to add this to my saved trials
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Pittsburgh, PA
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Fayetteville, TN
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Fayetteville, TN
Click here to add this to my saved trials
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Dallas, TX
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated:  8/2/2013
Clinical Research Facility
mi
from
Seattle, WA
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002 AM1)
Randomized, Phase II Study of MK-3475 Versus Chemotherapy in Patients With Advanced Melanoma
Status: Enrolling
Updated: 8/2/2013
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma
A Phase I-II Study of Treatment of Metastatic Melanoma Using Induction Therapy With Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab (BBI)
Status: Enrolling
Updated:  8/28/2013
San Francisco Oncology Associates
mi
from
San Francisco, CA
Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma
A Phase I-II Study of Treatment of Metastatic Melanoma Using Induction Therapy With Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab (BBI)
Status: Enrolling
Updated: 8/28/2013
San Francisco Oncology Associates
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  10/9/2013
Oncology Research Associates D/B/A
mi
from
Scottsdale, AZ
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 10/9/2013
Oncology Research Associates D/B/A
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  10/9/2013
Ucla Hematology/Oncology
mi
from
Los Angeles, CA
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 10/9/2013
Ucla Hematology/Oncology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  10/9/2013
H. Lee Moffitt Cancer Center & Research Inst, Inc
mi
from
Tampa, FL
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 10/9/2013
H. Lee Moffitt Cancer Center & Research Inst, Inc
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  10/9/2013
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 10/9/2013
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  10/9/2013
University of Louisville Medical Center
mi
from
Louisville, KY
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 10/9/2013
University of Louisville Medical Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  10/9/2013
Portland Providence Medical Center
mi
from
Portland, OR
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 10/9/2013
Portland Providence Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  10/9/2013
Md Anderson Can Cnt
mi
from
Houston, TX
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 10/9/2013
Md Anderson Can Cnt
mi
from
Houston, TX
Click here to add this to my saved trials
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  10/9/2013
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 10/9/2013
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies
A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies
Status: Enrolling
Updated:  10/10/2013
Stanford University School of Medicine
mi
from
Stanford, CA
A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies
A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies
Status: Enrolling
Updated: 10/10/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Ketoconazole On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib
Status: Enrolling
Updated:  10/28/2013
Clinical Research Facility
mi
from
Santa Clara, CA
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Ketoconazole On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib
Status: Enrolling
Updated: 10/28/2013
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Ketoconazole On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib
Status: Enrolling
Updated:  10/28/2013
Clinical Research Facility
mi
from
Ashville, NC
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Ketoconazole On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib
Status: Enrolling
Updated: 10/28/2013
Clinical Research Facility
mi
from
Ashville, NC
Click here to add this to my saved trials
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Ketoconazole On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib
Status: Enrolling
Updated:  10/28/2013
Clinical Research Facility
mi
from
Dallas, TX
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Ketoconazole On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib
Status: Enrolling
Updated: 10/28/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Ketoconazole On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib
Status: Enrolling
Updated:  10/28/2013
Clinical Research Facility
mi
from
Huntington, WV
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Ketoconazole On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib
Status: Enrolling
Updated: 10/28/2013
Clinical Research Facility
mi
from
Huntington, WV
Click here to add this to my saved trials
A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
A Phase I, Open-Label, Multicenter, 3-Period, Fixed-Sequence Study To Investigate The Effect Of Vemurafenib On The Pharmacokinetics Of A Single Dose Of Digoxin In Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Status: Enrolling
Updated:  10/28/2013
Clinical Research Facility
mi
from
Cleveland, OH
A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
A Phase I, Open-Label, Multicenter, 3-Period, Fixed-Sequence Study To Investigate The Effect Of Vemurafenib On The Pharmacokinetics Of A Single Dose Of Digoxin In Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Status: Enrolling
Updated: 10/28/2013
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Adaption of the Skin Sun Sensitivity Scale
Adaption of the Skin Sun Sensitivity Scale for People With All Pigment Varieties
Status: Enrolling
Updated:  11/1/2013
Northwestern University
mi
from
Chicago, IL
Adaption of the Skin Sun Sensitivity Scale
Adaption of the Skin Sun Sensitivity Scale for People With All Pigment Varieties
Status: Enrolling
Updated: 11/1/2013
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of Riluzole in Patients With Advanced Melanoma
Status: Enrolling
Updated:  11/18/2013
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of Riluzole in Patients With Advanced Melanoma
Status: Enrolling
Updated: 11/18/2013
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Intratumoral Injection Of Alpha-Gal Glycosphingolipids
Phase I Study To Evaluate The Toxicity And Feasibility Of Intratumoral Injection Of Alpha-Gal (Beta-galactosidase ) Glycosphingolipids In Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/11/2013
Universiity of Wisconsin
mi
from
Madison, WI
Intratumoral Injection Of Alpha-Gal Glycosphingolipids
Phase I Study To Evaluate The Toxicity And Feasibility Of Intratumoral Injection Of Alpha-Gal (Beta-galactosidase ) Glycosphingolipids In Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/11/2013
Universiity of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma
GM-CSF and Ipilimumab as Therapy in Metastatic Melanoma, a Phase II Study
Status: Enrolling
Updated:  12/13/2013
Northern Californai Melanoma Center, St. Mary's Medical Center
mi
from
San Francisco, CA
Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma
GM-CSF and Ipilimumab as Therapy in Metastatic Melanoma, a Phase II Study
Status: Enrolling
Updated: 12/13/2013
Northern Californai Melanoma Center, St. Mary's Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma
GM-CSF and Ipilimumab as Therapy in Metastatic Melanoma, a Phase II Study
Status: Enrolling
Updated:  12/13/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma
GM-CSF and Ipilimumab as Therapy in Metastatic Melanoma, a Phase II Study
Status: Enrolling
Updated: 12/13/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Status: Enrolling
Updated:  12/16/2013
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Status: Enrolling
Updated: 12/16/2013
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma
Phase 2 Trial of T-cell Based Low-dose Cyclophosphamide and Outpatient Intravenous Interleukin-2 in Metastatic Melanoma
Status: Enrolling
Updated:  1/9/2014
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma
Phase 2 Trial of T-cell Based Low-dose Cyclophosphamide and Outpatient Intravenous Interleukin-2 in Metastatic Melanoma
Status: Enrolling
Updated: 1/9/2014
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
Beverly Hills, CA
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
San Francisco, CA
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
Aurora, CO
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
New Haven, CT
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
Washington,
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
Washington,
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
Gainesville, FL
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
Miami Beach, FL
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
Chicago, IL
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  1/21/2014
Clinical Research Facility
mi
from
Springfield, MO
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of MK-3475 Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006 AM1)
A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 1/21/2014
Clinical Research Facility
mi
from
Springfield, MO
Click here to add this to my saved trials